Evogliptin

Clinical data
Trade names	Suganon
Other names	DA-1229
Routes of administration	By mouth
ATC code	A10BH07 (WHO)
Identifiers
IUPAC name (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-{[(2-methyl-2-propanyl)oxy]methyl}-2-piperazinone
CAS Number	1222102-29-5
PubChem CID	25022354
ChemSpider	26339341
UNII	09118300L7
KEGG	D11023
ChEMBL	ChEMBL1779710
CompTox Dashboard (EPA)	DTXSID00153545
Chemical and physical data
Formula	C19H26F3N3O3
Molar mass	401.430 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@@H](Cc2cc(c(cc2F)F)F)N
InChI InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1 Key:LCDDAGSJHKEABN-MLGOLLRUSA-N

Evogliptin (INN; trade names Suganon, Evodine) is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs.^[1] It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea^[2] and Russia.^[3]